GABA-A Agent SAGE-217: A New Antidepressant? - Gateway Psychiatric
sage-10k_20181231.htm
Emboldened By Sage's Zulresso Slip, Marinus Is Set To Succeed In PPD And Orphan Epilepsy (NASDAQ:MRNS) | Seeking Alpha
Sage Therapeutics' SAGE-217 Receives FDA's Breakthrough Designation for CNS Disorders
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration | Sage Therapeutics, Inc.
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Bait and Switch: the Great Ketamine “Breakthrough” | RxISK
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage Therapeutics Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder Does Not Meet
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder - Chemdiv
Sage shares up after FDA allows expedited depression drug development
Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics and Biogen Report Positive Phase 3 Data Showing Zuranolone Significantly Reduced Depressive Symptoms After Two Weeks
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Keeping up with the clinical advances: depression | CNS Spectrums | Cambridge Core
Zuranolone - Wikipedia
Sage surges after depression drug gets rapid path to approval - PMLiVE
Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia | BioSpace
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
Sage Therapeutics surges 70% after depression drug breakthrough
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder | Business Wire
SAGE Therapeutics shares rocket after FDA clearance to expedite its depression post-partum drug SAGE-217
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress | Business Wire
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
sage-10k_20161231.htm
Here's Why Sage Therapeutics Rose as Much as 20.3% Today | The Motley Fool
Sage Therapeutics Reports Positive Top-Line Results from Phase II Placebo-Controlled Trial of SAGE-217 in MDD - Drug Discovery and Development
